

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)



(10) International Publication Number
WO 2025/175056 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 40/15* (2025.01)
A61K 39/395 (2006.01) *A61K 40/31* (2025.01)
A61K 40/11 (2025.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2025/015857

(22) International Filing Date:

13 February 2025 (13.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/554,065 15 February 2024 (15.02.2024) US
63/712,349 25 October 2024 (25.10.2024) US

(71) Applicant: **NEXTPOINT THERAPEUTICS, INC.**

[US/US]; 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **ETEMAD-GILBERTSON, Bijan**; c/o Next-

Point Therapeutics, Inc., 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US). **RAUSCH, Matthew**; c/o NextPoint Therapeutics, Inc., 238 Main Street, 5th Floor, Cambridge, Massachusetts 02142 (US). **NIELSON, Nels**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). **BOLAND, Nadthakarn**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US).

(74) Agent: **ADAMS, Melissa M.** et al.; CHOATE, HALL &

STEWART LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: MULTISPECIFIC ANTIBODIES OR ANTIGEN BINDING FRAGMENTS THEREOF TO B7-H7 AND IMMUNE EFFECTOR CELL ANTIGENS




FIG. 1A

(57) Abstract: The present disclosure pertains to multispecific antibodies or antigen-binding fragments thereof, and methods of using such multispecific antibodies or antigen-binding fragments thereof. In some embodiments, the present disclosure provides multispecific antibodies or antigen-binding fragments thereof comprising: (i) a first antigen-binding domain that selectively binds to B7-H7, and (ii) a second antigen-binding domain that selectively binds an immune effector cell antigen. Such multispecific antibodies or antigen-binding fragments thereof disclosed herein can be used in methods of treating a subject having a disease, disorder, or condition and/or modulating an immune response in a subject.

WO 2025/175056 A1